Clinical trials: Suppurative Hidradenitis
Hidradenitis Suppurativa (HS)
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.
- Trial name
- NCT03894956
- Where
- 37 sites in Japan
- Volunteers
- 46 people
- Sponsor
- AbbVie
Atopic Dermatitis, Dermatology
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting.
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata
- Trial name
- ClinPRO-DERM (NCT05084417)
- Testing
- N/A This is an observational study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- OM1, Inc.
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
- Trial name
- NCT04856930
- Testing
- Imsidolimab
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- Vanda Pharmaceuticals
Hidradenitis Suppurativa
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS).
- Trial name
- NCT07228390
- Testing
- Ritlecitinib
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411899
- Testing
- Sonelokimab
- Where
- 109 sites in United States, Bulgaria and 8 more
- Volunteers
- 422 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa, Hidradenitis
HidraWear Study for Hidradenitis Suppurativa Wounds
The product, HidraWear AX (www.hidrawear.com) is and adhesive free wound dressing system for the every day home care of Hidradenitis Suppurativa (HS), a debilitating disease of the skin for which there are limited wound dressing…
- Trial name
- NCT04449354
- Testing
- HidraWear Ax
- Where
- Ireland
- Volunteers
- 16 people
- Sponsor
- HidraMed Solutions Ltd
Hidradenitis Suppurativa
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06956235
- Testing
- Tulisokibart
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 149 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent…
- Trial name
- STOP-HS LTE (NCT06212999)
- Testing
- Povorcitinib
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 617 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions.
- Trial name
- NCT04430855
- Testing
- Upadacitinib
- Where
- 26 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.
- Trial name
- SPECTRA (NCT06444087)
- Testing
- secukinumab
- Where
- 22 sites in France
- Volunteers
- 192 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in…
- Trial name
- NCT06785675
- Testing
- Secukinumab
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Herpes Genitalis, Genital Wart
Safety and Efficacy of Laser Therapy in Gynaecology
The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g.
- Conditions
- Herpes Genitalis, Genital Wart, Lichen Sclerosus, Cervical Intraepithelial Neoplasia
- Trial name
- NCT04073082
- Where
- Slovenia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Juna d.o.o.
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411379
- Testing
- Sonelokimab
- Where
- 106 sites in United States, Belgium and 10 more
- Volunteers
- 418 people
- Sponsor
- MoonLake Immunotherapeutics AG